



Exelixis R&D: Uniquely positioned to drive value creation



Exelixis pipeline of differentiated small molecules and biotherapeutics



Exelixis 2030 commercial vision: Multi-product, multi-modal solid tumor portfolio




LCM = life-cycle management
 mCRPC = metastatic castration-resistant prostate cancer
 NET = neuroendocrine tumors
 RCC = renal cell carcinoma
 HCC = hepatocellular carcinoma
 DTC = differentiated thyroid cancer
 MMAE = monomethyl auristatin E
 PD-(L)1 = programmed cell death protein 1 or programmed death-ligand 1
 NKG2A = natural killer cell receptor group 2A

TF = tissue factor
 TOPOi = topoisomerase inhibitor
 PKMYT1 = protein kinase membrane associated tyrosine/threonine 1
 ILT2 = Ig-like transcript 2
 MTI = auristatin-based microtubulin inhibitor
 USP-1 = ubiquitin specific peptidase 1
 SIRPα = signal-regulatory protein alpha
 PDC = peptide drug conjugate
 CRC = colorectal carcinoma


nccRCC = non-clear cell renal cell carcinoma
 SCCHN = squamous cell carcinoma of head and neck
 ICI = immune checkpoint inhibitor
 LAG-3 = lymphocyte-activation gene 3
 TIGIT = T-cell immunoglobulin and ITIM domain
 VEGF = vascular endothelial growth factor
 HIF2α = hypoxia-inducible factor 2 alpha
 H&N = head and neck
 CRPC = castration-resistant prostate cancer
 TKI = tyrosine kinase inhibitor



Build on cabozantinib clinical experience and leverage collaborations to accelerate pipeline development with goal of improving standard of care for patients



Discovering next-generation molecules with best-in-class potential



IO = immuno-oncology
 MOA = mechanism of action
 CTLA4 = cytotoxic T-lymphocyte-associated antigen 4
 CTX = chemotherapy
 NSCLC = non-small cell lung cancer